hsa-mir-3195: The mutant transcript contains an intron sequence of 192bp, which is a specific target of hsa-mir-3195 [PMC8877203]. For the miRNAs, hsa-mir-3195 and hsa-miR-4492, there were no targets found using miRDB, so only targets from Targetscan were used for analysis [PMC10138286]. This suggests that hsa-mir-3195, hsa-miR-3656, hsa-miR-4492, and hsa-miR-6087 could be sensitive biomarkers of HIV-1 infection in PBMCs after additional validation in patient samples [PMC7556008]. It is worth noting that hsa-mir-3195, hsa-miR-3656, hsa-miR-4492, and hsa-miR-6087 were detected only in the HIV-1-infected PBMC group and were not detected in the uninfected control group [PMC7556008]. According to the qRT-PCR data, hsa-mir-3195 was up-regulated in certain conditions [PMC4077747]. Hsa-mir-3195 was also found to have different expression levels compared to previous studies [PMC7196262]. However, no statistically significant difference was observed in the expression of hsa-mir-3195 between different groups in a TGF-beta1 study [PMC8351572]. In infants with BA, lower expression levels of hsa-mir-3195 were observed compared to controls [PMC4754688]. Hsa-mir-3195 was present in the nCounter probe set but not detected by nCounter assay and therefore excluded from subsequent analysis [PMC4478345]. In severe TBI cases, higher expression levels of hsa-mir-3195 were observed compared to mild and moderate cases [PMC6143266].